[{"id":"7b531ddf-9a02-4fe1-ae2a-1e80c3a63e7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125746","created_at":"2021-01-18T15:24:01.007Z","updated_at":"2024-07-02T16:36:36.596Z","phase":"Phase 1","brief_title":"A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT03125746","lead_sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • MTI-31"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/12/2017","start_date":" 06/12/2017","primary_txt":" Primary completion: 10/28/2021","primary_completion_date":" 10/28/2021","study_txt":" Completion: 10/28/2021","study_completion_date":" 10/28/2021","last_update_posted":"2021-01-05"}]